Introduction.

Neurodegenerative disorders are characterized by a degeneration and loss of nerve cells leading to cognitive and sensorimotor dysfunction disorders, such as multiple sclerosis (MS) and Parkinson’s disease (PD) among others. Recently, it has been reported promising results of cell therapy employing Mesenchymal Stem Cells, cells with the ability to differentiate into nervous tissue cells, in the treatment of neurological diseases.

Objective.

To expose the utility of bone marrow mesenchymal stem cells in the treatment of multiple sclerosis and Parkinson’s disease, as a therapeutic option in unfavorable treatment outcomes.

Material and methods.

Prospective longitudinal study that included MS (n=2) and PD (n=2) patients, who received autologous transplantation of bone marrow mesenchymal stem cells as adjuvant treatment.

Results.

Patients received autologous MSC therapy from 1 to 3 reinfusions, follow-up and regular evaluations reflected beneficial responses. Representative improvements concerning patients’ respectively EDSS or UPDRS scores, as well as in their quality of life were observed.

Conclusions.

Mesenchymal stem cells therapy constitutes a feasible therapeutic option for neurodegenerative disorders such as MS and PD.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )